June 23 2022 Acip Meeting Votes

Summary

Introductions; Moderna COVID-19 vaccine in children ages 6-17 years. Introduction; RSV virion & vaccine products; Epidemiology of RSV in children; Epidemiology of RSV in adults; Safety and efficacy ... Introduction; Overview of myocarditis and pericarditis; Update on COVID-19 vaccine safety, including myocarditis after mRNA ... MMR safety and immunogenicity; Public ; COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion. Introduction; PCV15 Pediatric Clinical Development Program – Update; Economic analysis and public health Impact of PCV15 ... Influenza Vaccine; Pneumococcal Vaccines; Pneumococcal Vaccines; MMR Vaccine. Safety, immunogenicity and efficacy of BNT162b2 in children ages 6 months through 4 years of age; mRNA COVID-19 vaccines in ... Human Papillomavirus; Pneumococcal Vaccines; VFC Evidence to Recommendations Clinical Considerations update, Introductions; Agency updates; Combined Immunization Schedule: 2023 child and adolescent schedule revisions; 2023 adult ... Introductions,GRADE: Evidence for Use of MenB Vaccines in Adolescents and Young Adults (including College Students),Public ...